Login / Signup

A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials.

Arnela Haagmans-SumanJasmijn van EsHelga GardarsdottirDiederick E GrobbeeKimberly HawkinsMegan A HeathIsla S MackenzieGhislaine van ThielMira G P Zuidgeestnull null
Published in: Trials (2022)
Decentralised methods are a widely implemented mitigation strategy for trial conduct in the face of the COVID-19 pandemic. The results of this survey show that there is an interest to continue the use of decentralised methods in future trials, but important points of attention have been identified that need solutions to help guide the transition from the traditional trial model to a more decentralised trial model.
Keyphrases
  • clinical trial
  • phase iii
  • phase ii
  • study protocol
  • coronavirus disease
  • sars cov
  • open label
  • randomized controlled trial
  • cross sectional